INmune Bio Says Study Shows Drug Candidate Reduced Alzheimer's-Related Brain Changes After Brain Injury
MT Newswires Live
Jul 15
INmune Bio (INMB) said Wednesday that a peer-reviewed preclinical study published in the Journal of Neurotrauma found its lead drug candidate, XPro1595, reduced Alzheimer's-related brain changes after traumatic brain injury in mice.
The Department of Defense-funded study found that brain injury increased inflammation and amyloid beta levels, both linked to Alzheimer's disease, it said. Treatment with XPro1595 prevented the rise in amyloid pathology and improved memory and pain outcomes, it added.
The company said the findings support further development of XPro1595 for neuroinflammation-driven Alzheimer's disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.